GlassScriptPhysician profile
Whitney S Scurlock
NPI 1215217526
$588.64
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $589.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $95.85 | 2021 | |
| Abbvie INC. | $95.01 | 2021 | |
| Novartis Pharmaceuticals Corporation | $88.33 | 2021 | |
| Lilly USA, LLC | $65.93 | 2021 | |
| Allergan, INC. | $42.23 | 2021 | |
| Sk Life Science, INC. | $39.88 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $39.57 | 2021 | |
| Ucb, INC. | $35.41 | 2021 | |
| Genentech USA, INC. | $33.25 | 2021 | |
| Avanir Pharmaceuticals, INC. | $15.17 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.44 | 2021 | |
| Biogen, INC. | $12.81 | 2021 | |
| Acadia Pharmaceuticals INC | $11.76 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Scurlock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.